

Evoluzioni 3D e nello speckle Tracking: sempre una promessa o una matura realtà diagnostica ?

Novità nel 3D transtoracico sul prolasso mitralico

Mauro Pepi, MD, FESC
Director Cardiac Imaging Dpt and Echo Laboratories
Centro Cardiologico Monzino, IRCCS
Dpt Cardiovascular Sciences.
University of Milan
ITALY



Napoli 2015



IMAGING CARDIOVASCOLARE

2D O 3D ?




TAC

MRI





Lusso o Necessità

Morfologia e funzione sono 3D




Historical Background



- Research activities.
- Nineties.....




- 2002 Real Time 3D
- Transcatheter
- commercial
- 2007 3D TEE




3D TEE
3DTTE



3D FREE-
HAND



3D LIVE
2002



“Free-hand” technique: Transmitter; Sensor/Receiver



Integrated circuit board combined with a position sensor attached to a commercial ultrasound transducer. The positioning sensor device registers translation and rotation of the transducer thus determining its position and orientation.

Post-processing: transform acquired data to cartesian coordinate system. Interpolation of undersampled regions.




Initial experience with a new on-line transthoracic three-dimensional technique: assessment of feasibility and of diagnostic potential

Mauro Pepi, Gloria Tamborini, GianLuca Pontone, Daniele Andreini, Giovanni Berna, Stefano De Vita, Anna Maltagliati

Centro Cardiologico Monzino, IRCCS, Milan, Italy

(Ital Heart J 2003; 4 (8))

- Clinical Trial in 83 adult patients



GUIDELINES AND STANDARDS

EAE/ASE Recommendations for Image Acquisition and Display Using Three-Dimensional Echocardiography

Roberto M. Lang, MD, FASE,*[‡] Luigi P. Badano, MD, FESC,^{†‡} Wendy Tsang, MD,* David H. Adams, MD,* Eustachio Agricola, MD,[†] Thomas Buck, MD, FESC,[†] Francesco F. Faletra, MD,[†] Andreas Franke, MD, FESC,[†] Judy Hung, MD, FASE,* Leopoldo Pérez de Isla, MD, PhD, FESC,[†] Otto Kamp, MD, PhD, FESC,[†] Jaroslaw D. Kasprzak, MD, FESC,[†] Patrizio Lancellotti, MD, PhD, FESC,[†] Thomas H. Marwick, MBBS, PhD,* Marti L. McCulloch, RDCS, FASE,* Mark J. Monaghan, PhD, FESC,[†] Petros Nihoyannopoulos, MD, FESC,[†] Natesa G. Pandian, MD,* Patricia A. Pellikka, MD, FASE,* Mauro Pepi, MD, FESC,[†] David A. Roberson, MD, FASE,* Stanton K. Shernan, MD, FASE,* Girish S. Shirali, MBBS, FASE,* Lissa Sugeng, MD,* Folkert J. Ten Cate, MD,[†] Mani A. Vannan, MBBS, FASE,* Jose Luis Zamorano, MD, FESC, FASE,[†] and William A. Zoghbi, MD, FASE*, *Chicago and Oak Lawn, Illinois; Padua and Milan, Italy; New York, New York; Essen and Hannover, Germany; Lugano, Switzerland; Boston, Massachusetts; Madrid, Spain; Amsterdam and Rotterdam, The Netherlands; Lodz, Poland; Liege, Belgium; Cleveland, Ohio; Houston, Texas; London, United Kingdom; Rochester, Minnesota; Charleston, South Carolina; New Haven, Connecticut; Morrisville, North Carolina*





(J Am Soc Echocardiogr 2012;25:3-46.)

2012



Data Acquisition Modes

- Simultaneous Multiplane Mode.
- Real-Time 3D Mode—Narrow Sector
- Focused Wide Sector—“ZOOM”.
- Full Volume—Gated Acquisition.





Protocollo 3D transtoracico




2002: Live 3D TTE

Sonde
dedicate





FLOW-CHART del PROTOCOLLO TTE

ECO 3D mai alternativo al 2D ma complementare




MAINLY INTRAOPERATIVE/Monitoring interventional procedures

REAL TIME
TEE 3D



MAINLY ROUTINE TRANSTHORACIC

REAL TIME
TT 3D



3,000 elements and breakthrough PureWave xMATRIX technology, the X5-1 supports virtually any cardiac ultrasound exam, including 3D, 2D, color flow, M-mode, PW/CW Doppler, Tissue Doppler imaging, and contrast-enhanced exams.


Sonde
Switch
2D/3D



FLOW-CHART del PROTOCOLLO TEE

ECO 3D mai alternativo al 2D ma complementare


**Sonde
2D-3D**



CAMPI APPLICATIVI DELL ECO 3D Transtoracico

- *PATOLOGIE CONGENITE*
- *MASSE CARDIACHE*
- ***VALVULOPATIE: prolasso mitralico***
- *FUNZIONE VENTRICOLARE SINISTRA*
- *FUNZIONE VENTRICOLARE DESTRA*
- *MONITORAGGI PROCEDURALI*

Severe MR in MV prolapse




2D and Color-Doppler

Indication and timing
Of MV surgery

LV diameters, volumes and EF
Left atrial dimensions
Severity of MR
Pulmonary Systolic Pressure

Management of Asymptomatic Severe Chronic Organic Mitral Regurgitation



GUIDELINES AND STANDARDS

EAE/ASE Recommendations for Image Acquisition and Display Using Three-Dimensional Echocardiography

Roberto M. Lang, MD, FASE, ^{*,†} Luigi P. Badano, MD, FESC, ^{†,‡} Wendy Tsang, MD, ^{*} David H. Adams, MD, ^{*}
Eustachio Agricola, MD, [†] Thomas Buck, MD, FESC, [†] Francesco F. Faletra, MD, [†] Andreas Franke, MD, FESC, [†]
Judy Hung, MD, FASE, ^{*} Leopoldo Pérez de Isla, MD, PhD, FESC, [†] Otto Kamp, MD, PhD, FESC, [†]
Jaroslaw D. Kasprzak, MD, FESC, [†] Patrizio Lancellotti, MD, PhD, FESC, [†] Thomas H. Marwick, MBBS, PhD, ^{*}
Marti L. McCulloch, RDCS, FASE, ^{*} Mark J. Monaghan, PhD, FESC, [†] Petros Nihoyannopoulos, MD, FESC, [†]
Natesa G. Pandian, MD, ^{*} Patricia A. Pellikka, MD, FASE, ^{*} Mauro Pepi, MD, FESC, [†]
David A. Roberson, MD, FASE, ^{*} Stanton K. Shernan, MD, FASE, ^{*} Girish S. Shirali, MBBS, FASE, ^{*}
Lissa Sugeng, MD, ^{*} Folkert J. Ten Cate, MD, [†] Mani A. Vannan, MBBS, FASE, ^{*}
Jose Luis Zamorano, MD, FESC, FASE, [†] and William A. Zoghbi, MD, FASE ^{*}, *Chicago and Oak Lawn, Illinois;
Padua and Milan, Italy; New York, New York; Essen and Hannover, Germany; Lugano, Switzerland; Boston,
Massachusetts; Madrid, Spain; Amsterdam and Rotterdam, The Netherlands; Lodz, Poland; Liege, Belgium;
Cleveland, Ohio; Houston, Texas; London, United Kingdom; Rochester, Minnesota; Charleston, South Carolina;
New Haven, Connecticut; Morrisville, North Carolina*

(J Am Soc Echocardiogr 2012;25:3-46.)

3D echocardiography may be superior to 2DE techniques and even direct inspection during surgery for diagnosing the location and extent of complex mitral valve disease, especially when commissural pathology or clefts are present.

“STATE OF THE ART” REVIEW ARTICLES

A Framework for Systematic Characterization of the Mitral Valve by Real-Time Three-Dimensional Transesophageal Echocardiography


Ernesto E. Salcedo, MD, Robert A. Quaife, MD, Tamas Seres, MD, and John D. Carroll, MD, *Denver, Colorado*

Table 1 Publications on 3D TEE of the MV


Reference	Population	Echocardiographic modalities	Assessment	Findings
Pepi et al ¹⁶	112 patients with MVP and severe MR	2D and 3D TTE, 2D TEE, 3D TEE (reconstruction)	MV repair surgery	3D TEE superior on description of pathology; 95% accuracy
Valocik et al ¹⁸	45 patients with MS	2D TTE, 2D TEE, 3D TEE (reconstruction)	Quantitative 3D echocardiography of MS	Funnel-like geometry may predict MS severity
Garcia-Orta et al ²⁵	81 patients with severe MR	2D TEE, 3D TEE (reconstruction)	MV repair surgery	3D better in A1 defects and commissures
Sugeng et al ¹⁴	211 patients referred for TEE	2D TEE, 3D MTEE	Image quality of native valves	85%-91% visualization of all MV scallops
Sugeng et al ¹²	40 prosthesis, 47 MV surgery	3D MTEE	Image quality, Surgical findings	Best for MVR; 96% surgical agreement
Grewal et al ²⁷	42 patients with MV repair	2D TEE, 3D TEE	Surgical inspection	3D TEE superior for P1, A2, A3, and bileaflet disease

MR, Mitral regurgitation; MS, mitral stenosis; MTEE, matrix-array TEE; MV, mitral valve; MVP, mitral valve prolapse; MVR, mitral valve prosthesis.




Fibro-elastic-deficiency



Barlow's Disease



Transthoracic 3D



Transesophageal 3D

Pre-operative evaluation of MV prolapse and the role of 3D Transthoracic Echocardiography

Has real time 3D transthoracic echo a role in facilitating the clinical decision making process in asymptomatic patients with MV prolapse and severe MR ?






Figure 5 Diagram of the mitral valve as seen from the left atrium. The anterior leaflet and its 3 segments (A1, A2, and A3) are posterior (P) to the left coronary cusp (LCC) and noncoronary cusp (NCC) of the aortic valve and adjacent to the aortomitral fibrosa (AMF) and the left fibrous trigone (LFT) and right fibrous trigone (RFT). The anterolateral commissure (ALC) is next to the left atrial appendage (LAA) and the A1 P1 scallops. The posteromedial commissure (PMC) is next to the A3 and P3 scallops. RCC, Right coronary cusp.

Journal of the American Society of Echocardiography
October 2009




Better evaluation of **morphologic abnormalities** and understanding of complex spatial orientation

Better **quantitative evaluation** (area and volume) (obviates any geometrical assumptions)

Facilitates **Training and Communication** between experts, non-experts and different specialists.

**IMPORTANZA
DIAGNOSI
MORFOLOGICA
3D**


MVP basale 3D Transtoracico




Head-to-Head Comparison of Two- and Three-Dimensional Transthoracic and Transesophageal Echocardiography in the Localization of Mitral Valve Prolapse

Mauro Pepi, MD, Gloria Tamborini, MD, Anna Maltagliati, MD, Claudia Agnese Galli, MD, Erminio Sisillo, MD, Luca Salvi, MD, Moreno Naliato, MD, Massimo Porqueddu, MD, Alessandro Parolari, MD, Marco Zanobini, MD, Francesco Alamanni, MD

Milan, Italy





..3DTTE and 2DTEE had similar accuracies (90 % and 87%, respectively), while the accuracy of 2DTT (77.2 %) was significantly lower.




.....since real time transthoracic 3D echo has an accuracy similar to that of 2D TEE new technique (which is also simple and rapid) may be integrated in the standard 2D examination and should be regarded as an important examination in decision regarding MV repair


Pepi et al JACC 2006

Prolasso P2





Severe MR




Zoom from the apical view: real time obtained in few seconds.

P1 prolapse; large scallop


A2-A3 prolapse

3DTTE



Visione dal
← ventricolo

Surgical
view →




3DTEE



FR 31Hz
15cmVolume completo
3D 25%
3D 23dB

M2




JPEG

Ritardo 0ms

Visione dal ventricolo

Surgical
viewFR 31Hz
15cmVolume completo
3D 20%
3D 17dB

M2





JPEG

Ritardo 0ms

51 bpm

NUOVA TECNOLOGIA 3DTTE 2014




Flail P 2 Isolato





Transtoracico 3D
Real Time




TranSESofageo 3D
Full Volume





Caso 1








Caso 1




P2 – P3



Caso 1





P2 – P3



Caso 2

Flail large
P2









Caso 2




Flail large P2



Caso 4




Barlow
P2- A2



Caso 4



Barlow
P2- A2




Caso 4


Impianto
Neo
Corde

Barlow
P2- A2






Caso 5




Report from another
hospital:
Chordal rupture Flail P2



Mild MR
Small
loculated P2
prolapse




Caso 5



Mild MR
Small
loculated
P2






Caso 6





Barlow
Very small
Posterior
Leaflet

Caso 6

Barlow
Large A2-A3




Caso 6



Barlow
Large A2-A3

Barlow
Very small
Posterior
Leaflet

Management of Asymptomatic Severe Chronic Organic Mitral Regurgitation




Early Surgery in Patients With Mitral Regurgitation Due to Flail Leaflets

A Long-term Outcome Study

Lieng H. Ling, MB, BS, MRCP; Maurice Enriquez-Sarano, MD;
James B. Seward, MD; Thomas A. Orszulak, MD; Hartzell V.
Schaff, MD; Kent R. Bailey, PhD; A. Jamil Tajik, MD; ; Robert L.
Frye, MD

Mayo Clinic and Mayo Foundation, Rochester, Minn.




Pts with flail MV
Early surgery vs
Conservative
management improved
long-term survival

Circulation 1997

Valvular Heart Disease

Outcome of Watchful Waiting in Asymptomatic Severe Mitral Regurgitation


Raphael Rozenhek, MD; Florian Rader, MD; Ursula Klar, MD; Harald Gabriel, MD; Marcel Krejci, PhD; Daniel Kalbeck, PhD; Michael Schemper, PhD; Gerald Maurer, MD; Helmut Baumgartner, MD



Asymptomatic pts with severe degenerative MR can be safely followed-up until their symptoms occur or currently recommended cutoff values for LV size, LV function or pulmonary hypertension are reached.

Circulation 2006

LONG-TERM RESULTS OF VALVE REPAIR WITH SIMPLE OR COMPLEX TECHNIQUES IN NONRHEUMATIC MV REGURGITATION



2008-2010: Nostra impostazione scientifica: è possibile predire tipo intervento con ECO 3D ?

ASSESSMENT OF REGURGITATION AFTER MITRAL VALVE REPAIR: follow-up

- 264 pts TT long term study.
- Mean freedoms from regurgitation:
- At 1 year : 91.5 %
- At 5 years: 47.5% (6.2% moderate)
- **Factors influencing MR:** poor LV function, age, chordal procedures.

Lim et Al J Thoracic Cardiovasc Surg 2002

SURVIVAL ADVANTAGE AND IMPROVED DURABILITY OF MITRAL REPAIR FOR LEAFLETS PROLAPSE SUBSETS IN THE CURRENT ERA

- 1441 ISOLATED MV PROLAPSE (MAYO)
- MV REPAIR 1173
- Factors influencing SURVIVAL younger age, better NYHA, no CAD.
- Adjusted for age : smaller LV eSV, EF
- Reoperation similar repair vs replacement

Reoperation 97 pts – 75 repairs (6%) mean 4.8 years

Factors predicting reoperation:

Younger age – anterior leaflet prolapse – chordal shortening
- No leaflet resection – no anuloplasty – greater than mild residual regurgitation, CAD.

Prevalence of Calcification of the Mitral Valve Annulus in Patients Undergoing Surgical Repair of Mitral Valve Prolapse


Laura Fusini, MS^{a,*}, Sarah Ghulam Ali, MD^a, Gloria Tamborini, MD^a, Manuela Muratori, MD^a, Paola Gripari, MD^a, Francesco Maffessanti, PhD^a, Fabrizio Celeste, MD^a, Marco Guglielmo, MD^a, Claudia Cefalù, MD^a, Francesco Alamanni, MD^{a,b}, Marco Zanobini, MD^a, and Mauro Pepi, MD^a

MAC is a common finding in patients undergoing MV repair, and several clinical characteristics correlate with MAC either in FED or BD.

Despite very high percentage of repairability, MAC influences surgical outcomes and very detailed echo evaluation is advocated.

Am J Cardiol 2014

The presence of MAC Influences surgical outcomes







Very high percentage of MV repair

Pre-operative transthoracic real-time three-dimensional echocardiography in patients undergoing mitral valve repair: accuracy in cases with simple vs. complex prolapse lesions


Gloria Tamborini*, Manuela Muratori, Anna Maltagliati, Claudia Agnese Galli, Moreno Naliato, Marco Zanobini, Francesco Alamanni, Luca Salvi, Erminio Sisillo, Cesare Fiorentini, and Mauro Pepi

Centro Cardiologico Monzino, IRCCS, Department of Cardiovascular Sciences, University of Milan, Via Parea 4, 20138 Milan, Italy


Received 5 February 2010; accepted after revision 25 April 2010




200 patients
3DTTE preop
2DTEE intraop
vs
Surgical
Inspection





63%
Complex






**90%
accuracy**





Prediction



Pre-operative transthoracic real-time three-dimensional echocardiography in patients undergoing mitral valve repair: accuracy in cases with simple vs. complex prolapse lesions

Gloria Tamborini*, Manuela Muratori, Anna Maltagliati, Claudia Agnese Galli, Moreno Naliato, Marco Zanobini, Francesco Alamanni, Luca Salvi, Erminio Sisillo, Cesare Fiorentini, and Mauro Pepi

Centro Cardiologico Monzino, IRCCS, Department of Cardiovascular Sciences, University of Milan, Via Parea 4, 20138 Milan, Italy

Received 5 February 2010; accepted after revision 25 April 2010



Real-time transthoracic 3D : Rapid Diagnosis of **simple and complex lesions** .




May facilitate **the prediction of the complexity of surgical procedures**.



May further facilitate the clinical decision and the correct timing (early surgery vs delayed procedures) .

Management of Asymptomatic Severe Chronic Organic Mitral Regurgitation



* valve repair can be considered when there is a high likelihood of durable valve repair at a low risk


Role of 3D

Morphology

Surgery
(repair whenever possible)



Intra-operatively


TEE



Pre-operatively

TTE





*Mitral valve repair is preferred over MVR when possible.

Table 17. Summary of Recommendations for Chronic *Primary* MR

Recommendations	COR	LOE	References
MV surgery is recommended for symptomatic patients with chronic severe primary MR (stage D) and LVEF >30%	I	B	(365, 376)
MV surgery is recommended for asymptomatic patients with chronic severe primary MR and LV dysfunction (LVEF 30%–60% and/or LVESD ≥40 mm, stage C2)	I	B	(359-362, 392-394)
MV repair is recommended in preference to MVR when surgical treatment is indicated for patients with chronic severe primary MR limited to the <u>posterior leaflet</u>	I	B	(87, 364, 395-409)
MV repair is recommended in preference to MVR when surgical treatment is indicated for patients with chronic severe primary MR involving the <u>anterior leaflet or both leaflets</u> when a successful and durable repair can be accomplished	I	B	(86, 407-413)
Concomitant MV repair or replacement is indicated in patients with chronic severe primary MR undergoing cardiac surgery for other indications	I	B	(414)
MV repair is reasonable in asymptomatic patients with chronic severe primary MR (stage C1) with preserved LV function (LVEF >60% and LVESD <40 mm) in whom the likelihood of a successful and durable repair without residual MR is >95% with an expected mortality rate of <1% when performed at a Heart Valve Center of Excellence	IIa	B	(39, 86, 415-419)
MV repair is reasonable for asymptomatic patients with chronic severe	IIa	B	(363, 415,



X MV repair is reasonable in asymptomatic patients with chronic severe primary MR (stage C1) with preserved LV function (LVEF >60% and LVESD <40 mm) in whom the likelihood of a successful and durable repair without residual MR is >95% with an expected mortality rate of <1% w (Center of Excellence)



Patients selection for MitraClip: Time to move to transthoracic echocardiographic screening?



Paola Gripari ^{a,1}, Francesco Maffessanti ^{a,*1}, Gloria Tamborini ^a, Manuela Muratori ^a, Laura Fusini ^a, Sarah Ghulam Ali ^a, Cristina Ferrari ^a, Francesco Alamanni ^{a,b}, Antonio L. Bartorelli ^{a,b}, Cesare Fiorentini ^{a,b}, Mauro Pepi ^a




^a Centro Cardiologico Monzino, IRCCS, Milan, Italy

^b Department of Clinical Sciences and Community Health – Cardiovascular Section, University of Milan, Milan, Italy



Feldman et al, NEJM 2011 (EVEREST II)

Flail Gap and Width





Feldman et al, JACC 2009 (EVEREST)



Anatomic criteria Degenerative MR

Advances in TTE and 3D echo may further improve our understanding of this new procedure



3D Echocardiography



Patient specific mode



Computational fluid dynamics



GUIDELINES AND STANDARDS

EAE/ASE Recommendations for Image Acquisition and Display Using Three-Dimensional Echocardiography

Roberto M. Lang, MD, FASE,*[‡] Luigi P. Badano, MD, FESC,^{†‡} Wendy Tsang, MD,* David H. Adams, MD,* Eustachio Agricola, MD,[†] Thomas Buck, MD, FESC,[†] Francesco F. Faletra, MD,[†] Andreas Franke, MD, FESC,[†] Judy Hung, MD, FASE,* Leopoldo Pérez de Isla, MD, PhD, FESC,[†] Otto Kamp, MD, PhD, FESC,[†] Jaroslaw D. Kasprzak, MD, FESC,[†] Patrizio Lancellotti, MD, PhD, FESC,[†] Thomas H. Marwick, MBBS, PhD,* Marti L. McCulloch, RDCS, FASE,* Mark J. Monaghan, PhD, FESC,[†] Petros Nihoyannopoulos, MD, FESC,[†] Natesa G. Pandian, MD,* Patricia A. Pellikka, MD, FASE,* Mauro Pepi, MD, FESC,[†] David A. Roberson, MD, FASE,* Stanton K. Shernan, MD, FASE,* Girish S. Shirali, MBBS, FASE,* Lissa Sugeng, MD,* Folkert J. Ten Cate, MD,[†] Mani A. Vannan, MBBS, FASE,* Jose Luis Zamorano, MD, FESC, FASE,[†] and William A. Zoghbi, MD, FASE*, *Chicago and Oak Lawn, Illinois; Padua and Milan, Italy; New York, New York; Essen and Hannover, Germany; Lugano, Switzerland; Boston, Massachusetts; Madrid, Spain; Amsterdam and Rotterdam, The Netherlands; Lodz, Poland; Liege, Belgium; Cleveland, Ohio; Houston, Texas; London, United Kingdom; Rochester, Minnesota; Charleston, South Carolina; New Haven, Connecticut; Morrisville, North Carolina*

(J Am Soc Echocardiogr 2012;25:3-46.)

Three-dimensional TTE and TEE assessments of mitral valve pathology should be incorporated **into routine clinical practice** as they provide the best physiologic and morphologic information regarding the mitral valve. 3D TEE is recommended for guidance of interventional mitral valve procedures.